MS disease activity in RESTORE A randomized 24-week natalizumab treatment interruption study

Jahr

2014

Autoren

Fox RJ, Cree BA, De Sèze J, Gold R, Hartung HP, Jeffery D, Kappos L, Kaufman M, Montalbán X, Weinstock-Guttman B, Anderson B, Natarajan A, Ticho B, Ziemssen T, Duda P; RESTORE.

Verlag

Neurology. 2014 Apr 29;82(17):1491-8.

Link

https://doi.org/10.1212/wnl.0000000000000355

MS disease activity in RESTORE A randomized 24-week natalizumab treatment interruption study

Ziemssen T, Centonze D. Diagnostic uncertainty in the era of biosimilar natalizumab-The case for harmonizing anti-JCV antibody testing. Mult Scler. 2025 Jun;31(7):751-753. doi: 10.1177/13524585251346658. Epub 2025 Jun 14. PMID: 40515640.

Speech as a digital biomarker in multiple sclerosis: Automatic analysis of speech metrics using a multi-speech-task protocol in a cross-sectional MS cohort study

CONFIDENCE treatment success: long-term real-world effectiveness and safety of ocrelizumab in Germany

RECLAIM—A retrospective, multicenter observational study aimed at enabling the development of artificial intelligence-driven prognostic models for disease progression in multiple sclerosis

Experiences of People with Multiple Sclerosis in Sensor-Based Jump Assessment